| Jason M. Hollar | Chief Executive Officer | FY2026 | |
| Aaron E. Alt | Chief Financial Officer | FY2026 | |
| Deborah L. Weitzman | Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment | FY2026 | |
| Jessica L. Mayer | Chief Legal and Compliance Officer | FY2026 | |
| Stephen M. Mason | Chief Executive Officer, Global Medical Products and Distribution Segment | FY2026 |
5 executives
Named executives and their total pay come from the Summary Compensation Table of the latest proxy statement.